Immuneering Corporation

Equities

IMRX

US45254E1073

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.37 ^USD	-2.84%		-1.44%	-81.36%

May. 07	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2022

March 06, 2023 at 04:07 pm EST

Immuneering Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 0.316952 million compared to USD 2.08 million a year ago. Net loss was USD 50.51 million compared to USD 33.54 million a year ago.

Basic loss per share from continuing operations was USD 1.91 compared to USD 2.46 a year ago.

Latest news about Immuneering Corporation

Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	Apr. 09	CI
Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	Apr. 02	MT
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	Mar. 27	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	Mar. 15	MT
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16	Mar. 15	MT
Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating	Mar. 15	MT
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating	Mar. 15	MT
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Guggenheim Downgrades Immuneering to Neutral From Buy	Mar. 15	MT
TD Cowen Downgrades Immuneering to Market Perform From Outperform	Mar. 15	MT
Transcript : Immuneering Corporation - Special Call	Mar. 14
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	Mar. 14	CI
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors	Mar. 12	CI
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	Mar. 11	MT
Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	Mar. 11	CI
Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 01	CI
Immuneering Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 01	CI
Immuneering Receives FDA's Fast Track Designation for IMM-1-104 in Pancreatic Cancer	Feb. 20	MT
Immuneering Shares Rise After FDA Fast-Track Status for Pancreatic Cancer Treatment	Feb. 20	DJ
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	Feb. 20	CI
Immuneering Corporation(NasdaqGM:IMRX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI

Chart Immuneering Corporation

Duration

Period

More charts

Company Profile

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Companyâs lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Companyâs second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Companyâs platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.37 USD

Average target price

13.71 USD

Spread / Average Target

+901.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUNEERING CORPORATION	-81.36%	40.63M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research